Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasm Metastasis × BID protein, human × Clear all

Phase

Status

Terminated 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 1 Neoplasms by Histologic Type 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia 1 Hematologic Diseases 1 Granulosa Cell Tumor 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Bone Marrow Diseases 1 Advanced Solid Tumor 1

Interventions

pembrolizumab 23 Capecitabine 21 Cyclophosphamide 20 Bevacizumab 20 Gemcitabine 18 aldesleukin 17 Fluorouracil 17 Nivolumab 16 Docetaxel 16 Leucovorin 15 Paclitaxel 14 Irinotecan 14 Radiosurgery 13 Interleukin-2 13 fludarabine 12 Oxaliplatin 12 fludarabine phosphate 10 Drug Therapy 10 Cisplatin 10 Albumin-Bound Paclitaxel 10 Cetuximab 9 Carboplatin 9 Radiotherapy 8 Everolimus 8 Doxorubicin 8 Zoledronic Acid 7 Trastuzumab 7 Temozolomide 7 Sunitinib 7 Erlotinib Hydrochloride 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02101684 2018-03-05

Greko II

Grupo Español de Tumores Huérfanos e Infrecuentes

Phase 2 Terminated

Granulosa Cell Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡